## Fentanyles use in Estonia \* not misuse of pharmaceutical opioids

**TDI** expert meeting 19-20.09.2012

Ave Talu

National Institute for Health Development
Estonian Drug Monitoring Centre

## ntanyles use in Estonia (1)

ne synthetic opioid fentanyl is used widely for managing chronic and ca in

comparision to the potential of morphine fentanyl is 80 – 200, αethylfentanyl 200 – 1000, 3-methylfentanyl 6000 – 7000 times more werful

llowing a heroin shortage in 2001, illicit fentanyl produced in illegal ndestine laboratories were introduced to the illicit drug market in Est 02 causing a sharp increase in fatal drug poisoning

e number of lethal poisonings caused by the use fenatnyl was remarka sh in 2002-2009 (incl. lethal poisonings due to the usage of 3-methylfe

cit fentanyl produced in illegal clandestine laboratories mainly origina om Russia

#### ntanyles use in Estonia (2)

Based on data from cross-sectional studies of HIV prevalence and related risk behaviour conducted among IDUs in Estonia shift in use from heroin and home-made opiates to fentanyles and amphetamine has occurred in recent years (Platt et al., 2006; Uusküla et al., 2006; Wilson et al., 2007; Uusküla et al., 2008; Abel-O et al., 2009; Talu et al., 2010; Uusküla et al., 2010; Vorobjov et al, 2011

Illegally produced fentanyles sold in powder form in Estonia are administrated by intravenous injection, and recent years smoking or inhalation

## ntanyl use in Estonia (3)

ualitative research conducted among IDUs by Vorobjov and her colleag owed that

clusive injectors preferred injecting to other routs of administration e rapid / intense effects and its convenience

- ther rout of administration than injecting of fenatnyl were used to mirms:
  - -related with injection (protect veins or if no syringe was available
  - -prevent drug-related overdose when the quality (purity) of fentanyl was not known

probjov S, Uusküla A,Des Jarlais D C, , Abel-Ollo K, Talu A, Rüütel K. (2012) . Multiple routes of drug Idministration and HIV risk among injecting drug users. Journal of Substance Abuse Treatment, 42(4

## evalence of drug use among general population aged 15 to 6 2008 (%)

| Drug            | Prevalence | in last 12 n | nonths (%) | Prevalence in last 30 days (%) |       |       |  |
|-----------------|------------|--------------|------------|--------------------------------|-------|-------|--|
|                 |            | 15-64        |            | 15-64                          |       |       |  |
|                 | Men        | Women        | Total      | Men                            | Women | Total |  |
| Cannabis        | 8.3        | 3.8          | 6.0        | 1.7                            | 1.1   | 1.4   |  |
| Heroin          | 0.4        | 0            | 0.1        | 0                              | 0     | 0     |  |
| Cocaine         | 0.8        | 0.4          | 0.6        | 0                              | 0.1   | 0.1   |  |
| Amphetamine     | 1.3        | 0.8          | 1.0        | 1.0                            | 0     | 0.5   |  |
| Ecstasy         | 1.6        | 0.8          | 1.2        | 0.3                            | 0.1   | 0.2   |  |
| LSD             | 0.2        | 0.2          | 0.2        | 0                              | 0     | 0     |  |
| Sleeping pills/ | 11.2       | 22.6         | 17.1       | 7.7                            | 14.9  | 11.4  |  |
| tranquilisers   |            |              |            |                                |       |       |  |
| GHB             | 0.2        | 0.1          | 0.1        | 0                              | 0.1   | 0.1   |  |
| Fentanyl        | 0.2        | 0            | 0.1        | 0                              | 0     | 0     |  |
| Popper          | 0.8        | 0.8          | 0.8        | 0                              | 0.2   | 0.1   |  |

## evalence of drug use among general population aged 15 to 2 of drug use among general population aged 15 to 2 of 25-34 in 2008 (%)

| Prevalence in last 12 months (%) |                                    |  |  |   | Prevalence in last 30 days (%)   |   |   |   |   |  |  |
|----------------------------------|------------------------------------|--|--|---|--|---|---|---|---|--|--|
| 15-24                            |                                    |  | 25-34  |   |  | 15-24   |   |   | 25-34   |  |  |
| М                                | F                                  | Т  | М  | F   | Т  | M   | F   | Т   | М   | F  | -  |
| 26                               | 12.3                               | 19.8   | 9.2  | 6.7   | 7.6  | 6.5   | 4.1   | 5.3   | 0.8   | 1.3  | 1.   |
| 2.2                              | 0                                  | 0.8  | 0  | 0   | 0  | 0   | 0   | 0   | 0   | 0  | 0  |
| 1.3                              | 2.6                                | 2.0  | 1.3  | 0   | 0.7  | 0   | 0.7   | 0.3   | 0   | 0  | 0  |
| 4.6                              | 2.7                                | 3.7  | 1.3  | 1.3   | 1.3  | 4.6   | 0   | 2.3   | 0   | 0  | 0  |
| 3.3                              | 3.3                                | 3.3  | 2.0  | 0.7   | 1.3  | 1.3   | 0.7   | 1.0   | 0   | 0  | 0  |
| 1.1                              | 1.3                                | 1.2  | 0  | 0   | 0  | 0   | 0   | 0   | 0   | 0  | 0  |
| 6.5                              | 17.9                               | 13.6   | 10.4   | 14.8  | 12.6   | 4.6   | 8.7   | 6.3   | 7.2   | 10.7   | 8.   |
| 0                                | 0                                  | 0  | 0.8  | 0.5   | 0.7  | 0   | 0   | 0   | 0   | 0  | 0  |
| 1.1                              | 0                                  | 0.4  | 0  | 0   | 0  | 0   | 0   | 0   | 0   | 0  | 0  |
| 2.2                              | 4.0                                | 3.3  | 1.7  | 0.5   | 1.0  | 0   | 0.7   | 0.4   | 0   | 0.5  | 0.   |
|                                  | M 26 2.2 1.3 4.6 3.3 1.1 6.5 0 1.1 | 15-24 M F 26 12.3 2.2 0 1.3 2.6 4.6 2.7 3.3 3.3 1.1 1.3 6.5 17.9 0 0 1.1 0 | 15-24MFT2612.319.82.200.81.32.62.04.62.73.73.33.33.31.11.31.26.517.913.60001.100.4 | 15-24         M       F       T       M         26       12.3       19.8       9.2         2.2       0       0.8       0         1.3       2.6       2.0       1.3         4.6       2.7       3.7       1.3         3.3       3.3       3.3       2.0         1.1       1.3       1.2       0         6.5       17.9       13.6       10.4         0       0       0.8         1.1       0       0.4       0 | 15-24       25-34         M       F       T       M       F         26       12.3       19.8       9.2       6.7         2.2       0       0.8       0       0         1.3       2.6       2.0       1.3       0         4.6       2.7       3.7       1.3       1.3         3.3       3.3       3.3       2.0       0.7         1.1       1.3       1.2       0       0         6.5       17.9       13.6       10.4       14.8         0       0       0.8       0.5         1.1       0       0.4       0       0 | 15-24       25-34         M       F       T       M       F       T         26       12.3       19.8       9.2       6.7       7.6         2.2       0       0.8       0       0       0         1.3       2.6       2.0       1.3       0       0.7         4.6       2.7       3.7       1.3       1.3       1.3         3.3       3.3       3.3       2.0       0.7       1.3         1.1       1.3       1.2       0       0       0         6.5       17.9       13.6       10.4       14.8       12.6         0       0       0.8       0.5       0.7         1.1       0       0.4       0       0       0 | 15-24       25-34       Image: Colspan="4" of the colspan="4" | 15-24         M       F       T       M       F       T       M       F         26       12.3       19.8       9.2       6.7       7.6       6.5       4.1         2.2       0       0.8       0       0       0       0       0         1.3       2.6       2.0       1.3       0       0.7       0       0.7         4.6       2.7       3.7       1.3       1.3       1.3       4.6       0         3.3       3.3       2.0       0.7       1.3       1.3       0.7         1.1       1.3       1.2       0       0       0       0       0         6.5       17.9       13.6       10.4       14.8       12.6       4.6       8.7         0       0       0       0.5       0.7       0       0         1.1       0       0.4       0       0       0       0       0 | 15-24         M       F       T       M       F       T       M       F       T         26       12.3       19.8       9.2       6.7       7.6       6.5       4.1       5.3         2.2       0       0.8       0       0       0       0       0       0         1.3       2.6       2.0       1.3       0       0.7       0       0.7       0.3         4.6       2.7       3.7       1.3       1.3       1.3       4.6       0       2.3         3.3       3.3       3.3       2.0       0.7       1.3       1.3       0.7       1.0         1.1       1.3       1.2       0       0       0       0       0       0         6.5       17.9       13.6       10.4       14.8       12.6       4.6       8.7       6.3         0       0       0       0       0       0       0       0       0         1.1       0       0.4       0       0       0       0       0       0 | 15-24       15-24       15-24       Interval of the product of th | 15-24       25-34         M       F       T       M       F       T       M       F       T       M       F       T       M       F         26       12.3       19.8       9.2       6.7       7.6       6.5       4.1       5.3       0.8       1.3         2.2       0       0.8       0       0       0       0       0       0       0       0         1.3       2.6       2.0       1.3       0       0.7       0       0.7       0.3       0       0         4.6       2.7       3.7       1.3       1.3       1.3       4.6       0       2.3       0       0         3.3       3.3       3.3       2.0       0.7       1.3       1.3       0.7       1.0       0       0         1.1       1.3       1.2       0 |

oss-sectional study of risk behaviour and HIV status conducted amon Us in Tallinn and Kohtla-Järve in 2007 (source: National Institute for Palth Development and University of Tartu, 2008)

|                                     |      | EPP*      |  |  |
|-------------------------------------|------|-----------|--|--|
|                                     | %    | 95% CI    |  |  |
| Main drug injected during last 4 we | eks  |           |  |  |
| RDS study in Tallinn                |      |           |  |  |
| Fentanyl                            | 64.2 | 53.7-74.4 |  |  |
| Amphetamine                         | 33.5 | 23.1-44.1 |  |  |
| Heroin                              | 0.6  | 0-1.6     |  |  |
| Sudafed                             | 0.3  | 0-1.1     |  |  |
| RDS study Kohtla-Järve              |      |           |  |  |
| Fentanyl                            | 18.2 | 12.3-24.7 |  |  |
| Amphetamine                         | 16.2 | 10.7-22.3 |  |  |
| Poppy liquid                        | 49.5 | 41.7-57.0 |  |  |
| Heroin                              | 9.8  | 5.2-15.6  |  |  |
| Sudafed                             | 0.6  | 0-2.3     |  |  |
| Other                               | 6.7  | 0.4-7.5   |  |  |

## oss-sectional RDS study of risk behaviour and HIV am US (Tallinn 2007 and 2009)

|                              | overall |          | reported starting |           | reported s |   |
|------------------------------|---------|----------|-------------------|-----------|------------|---|
|                              |         |          | injecting d       | injecting | at         |   |
|                              |         |          | 15 years o        | or older  |            |   |
|                              | n       | %        | n                 | %         | n          |   |
| drug injected last 6 months) |         |          |                   |           |            |   |
| anyl                         | 411     | 61       | 105               | 67        | 305        |   |
| hetamine                     | 174     | 26       | 33                | 22        | 141        |   |
| ad nin-fatal overdose        |         |          |                   |           |            |   |
|                              | 232     | 34       | 45                | 29        | 186        |   |
|                              | 441     | 66       | 111               | 71        | 330        |   |
|                              |         | <u> </u> |                   | 1         | <u>. I</u> | I |

jov, S., et al Socio-demographic factors, health risks and harms associated with early initiation of ing people who inject drugs in Tallinn, Estonia: Evidence from cross-sectional surveys. International J

oss-sectional study of risk behaviour and HIV status conduct nong IDUs in Narva (source: National Institute for Health evelopment, 2011)

|              | EPP                    |  |  |  |
|--------------|------------------------|--|--|--|
| n            | %                      | 95% CI   |  |  |
| weeks        |                        |  |  |  |
| 225          | 70.5                   | 62.7-77.9                                      |  |  |
| 67           | 13                     | 8.9-19.5                                       |  |  |
| 39           | 10.6                   | 6.2-14.9                                       |  |  |
| 13           | 2.8                    | 1.0-4.7  |  |  |
| 1            | 2.1                    | 0-5.3  |  |  |
| 5            | 1                      | 0.1-2.3  |  |  |
| - <b>!</b> - | weeks  225  67  39  13 | weeks  225 70.5  67 13  39 10.6  13 2.8  1 2.1 |  |  |

## mparison of HIV infection and risk behaviour of primary fen d amphetamine injectors in Tallinn

- % (256/331) of participants reported fentanyl and 23% (75/331) ophetamine as their main drug of injection
- ulti-drug injection was reported by 53% across the whole sample
- % primary amphetamine injectors and 43% fentanyl users injected on ain drug
- mparison of ampethamine injectors, fentanyl injectors had higher odd
- erdose (AOR = 3.02, 95% CI: 1.65–5.54)
- ring a needle/syringe with an HIV positive person (AOR = 3.00, 95% CI: 1.33–6.79)
- cting in the street using a needle/syringe someone had used before (AOR = 2.39, 9 4–5.04).
- time drug treatment 2.49 (95% CI: 1.24–5.00)
- ng HIV positive (AOR = 2.89, 95% CI: 1.55–5.39)

## ug-related deaths caused by fentanyles (1)

888 drug-related deaths occurred in Estonia during the period of 2000 (Tuusov et al 2012)

Most of those who died due to illegal drug poisoning were male (N=78 and aged 16-34 (N=764)


The average age of those who died were 28.1

65.3% of all lethal drug poisonings were caused by fentanyles

Illegal drug poisoning with 3-methylfentanyl (45.7%) and fentanyl (19. ranking highest (N=580; in total 65.3% all cases), followed by morphine/heroin (10.8%), amphetamine (7.2%) and methadone (6.3%)

ov Let al-Fatal noisonina in Estonia 2000-2009. Trends in illegal drug-related dea

egal drugs causing most fatal drug poisonings in Estonia 200 009



ov I. Rt al.. Fatal noisonina in Estonia 2000-2009. Trends in illegal drug-related dea

ortality due to drug induced deaths per million population a —64 years



### Drug-related deaths caused by fentanyles (1)

usov and her colleagues from the Estonian Forensic Science Institute ggested that:

inding 3-methylfentanyl and fentanyl in blood samples indicates the pure/incorrect synthesis of both above mentioned illicit drugs in illegandestine laboratories

atal poisoning involving fentanyles was frequently combined with aphetamines

entanyles combined with amphetamine - Estonian version of 'speedba

ny Let al-Eatal noisonina in Estonia 2000-2009. Trends in illegal frug-related deat

#### onclusion

e fentanyl (illegally produced!) injection epidemic among IDUs in Estonia is the lor ported such epidemic in Europe

was probably caused by changes in local illegal drug market (heroin shortage in 20 e shortage of heroin probably contributed to an increase in the injection of

- egally produced fentanyles have continue to be the predominant opiates used mai Us and lately among NIDUs in the Estonian
- ose to two-third of lethal drug poisonings during the period of 2000-2009 were can
- V prevalence among primary fentanyl injectors is very high (62%) (95% CI: 56.97–nich is significantly higher (at p < 0.001 level) comparing amphetamine injectors (2 : 18.45–35.51).
- 05 cross-sectional RDS study among IDUs (N=331) (Talu et al., 2010)

nphetamines, but this needs to be studied further

Us who injected fentanyl (only or fentanyl +amphetamine) in the past 6 months wore likely to be HIV positive compared with IDUs injecting amphetamine only (63% %, p < .001).

# Thank you!